RAS family variants—most of which involve KRAS—are the most commonly occurring
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …

Cells rely on the endoplasmic reticulum (ER) to fold and assemble newly synthesized
transmembrane and secretory proteins—essential for cellular structure–function and for both …

Eukaryotic cells are equipped with an intricate proteostasis network (PN), comprising nearly
3,000 components dedicated to preserving proteome integrity and sustaining protein …

The unfolded protein response (UPR) is a mechanism aiming at restoring endoplasmic
reticulum (ER) homeostasis and is likely involved in other adaptive pathways. The UPR is …

KRAS is a small GTPase that is among the most commonly mutated oncogenes in cancer.
Here, we discuss KRAS biology, therapeutic avenues to target it, and mechanisms of …

Abstract Ubiquitin-fold modifier 1 (UFM1) is covalently conjugated to protein substrates via a
cascade of enzymatic reactions, a process known as UFMylation. UFMylation orchestrates …

Abstract KRAS G12C mutations in non-small cell lung cancer (NSCLC) partially respond to
KRAS G12C covalent inhibitors. However, early adaptive resistance occurs due to rewiring …

The Kirsten rat sarcoma viral oncoprotein homolog (KRAS) is currently a primary focus of
oncologists and translational scientists, driven by exciting results with KRAS-targeted …

Non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) are associated with a
high mortality rate. Mutations in the V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog …

Direct targeting of the KRAS-G12C–mutant protein using covalent inhibitors (G12Ci) acts on
human non–small cell lung cancer (NSCLC). However, drug resistance is an emerging …